A study to estimate the proportion of inflammatory bowel disease (IBD) patients needing biological agents and reasons for discontinuation of biologics in our patient population.

Dr Tarun Gupta0 个研究点目标入组 495 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. All patients with a confirmed diagnosis of IBD based on diagnostic criteria of IBD
•Copenhagen Diagnostic Criteria (UC) (all three criteria must be present):
•(i) History of diarrhea and/or rectal bleeding and pus for more than 1 week or repeated episodes.
•(ii) Characteristic endoscopic findings of continuous ulceration, vulnerability or granulated mucosa.
•(iii) Histopathology consistent with UC (neutrophils within epithelial structures, cryptitis, crypt distortion, crypt abscesses).
•Infection and cancer should be ruled out.
•Copenhagen Diagnostic Criteria (CD) (at least two criteria must be present):
•(i) History of abdominal pain, weight loss and/or diarrhoea for more than 3 months.
•(ii) Characteristic endoscopic findings of ulceration (aphthous lesions, snail track ulcerations), or cobble stoning, or radiological features of stricture.
•(iii) Histopathology consistent with CD (epithelioid granuloma of Langhans type or transmural, discontinuous focal or patchy inflammation).
•(iv) Fistula and/or abscesses in addition to affected bowel segments.
•Infection and cancer should be ruled out.
•2. Age group: all age groups

•Patients with Inflammatory Bowel Disease (IBD) not giving consent for the study

发起方

Dr Tarun Gupta